Eli Lilly & Co

How Eli Lilly’s $1T milestone and GLP‑1 drugs Mounjaro & Zepbound are reshaping weight‑loss treatment and driving market growth.

Discover how Eli Lilly’s GLP‑1 platform and dual‑agonist pipeline propelled its market cap beyond $1 trillion, reshaping obesity therapy and investor confidence.

Explore Eli Lilly’s 126.6% revenue surge, fueled by Mounjaro and Zepbound, and why its diversified pipeline keeps the pharma stock poised for growth amid fierce competition and macro risks.

Eli Lilly’s stock price has surged by nearly 6% after its weight-loss medication, Orforglipron, met its primary goals in a Phase 3 trial, bringing it closer to regulatory approval.

Eli Lilly & Co.’s stock price surged by 6% after positive study results for its treatments, including Orforglipron and Verzenio, and Zepbound’s success in a recent trial.

Eli Lilly’s stock price has plummeted from a 52-week high of nearly $1,000 to $624, but analysts predict a potential rebound due to new price targets and a surge in investor interest.

Eli Lilly & Co’s stock price has shown a 2.7% increase following insider buying activity, while the company also raised the list price of its diabetes drug Mounjaro in the UK.

Eli Lilly & Co has announced a 170% price hike for its diabetes treatment Mounjaro in the UK, aligning with European market prices, as part of a broader strategy to boost its financials.

Eli Lilly & Co’s stock has taken a hit, but analysts remain optimistic about the company’s growth prospects, citing strong quarterly results and a promising pipeline of treatments.

Eli Lilly’s stock price has been volatile despite strong quarterly earnings and high demand for its medications, leaving investors puzzled and uncertain about its future direction.